

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION
中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1763)

APPOINTMENT OF EMPLOYEE REPRESENTATIVE DIRECTOR

In accordance with the Company Law of the People's Republic of China and applicable laws and regulations, as well as the Articles of Association of China Isotope & Radiation Corporation (the "**Company**", together with its subsidiaries, the "**Group**"), the Company held an employee meeting on 10 November 2023 and elected Mr. Fan Guomin ("**Mr. Fan**") as the employee representative director of the Company.

The biographical detail of Mr. Fan is set out below:

Mr. Fan Guomin (范國民), aged 53, is currently a deputy general manager of the Company. From March 2017 to March 2018, Mr. Fan served as the chairman of Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. (深圳市中核海得威生物科技有限公司). From June 2017 to April 2019, he served as the chairman of HTA Co., Ltd. (原子高科股份有限公司). From July 2017 to April 2019, he served as the chairman of Chengdu Gaotong Isotope Co., Ltd. (CNNC) (成都中核高通同位素股份有限公司). From March 2016 to April 2020, he served as the deputy chairman of Beijing CIAE-RIAR Radioisotope Technology Co., Ltd. (北京雙原同位素技術有限公司). Since January 2017, he has been serving as the deputy chairman of Shanghai Xinke Pharmaceutical Co., Ltd. (上海欣科醫藥有限公司). From April 2017 to February 2022, he served as the deputy chairman of Shenzhen CICAM Manufacturing Co., Ltd.* (深圳西卡姆同位素有限公司). Since May 2018, he has been the vice president of Beijing Radiation Safety Research Association (北京市輻射安全研究會). Since November 2020, he has been a director of Nuclear Medicine Branch of Chinese Nuclear Society (中國核學會核醫學分會). Since June 2021, he has been a director of the Nuclear Environmental Protection Branch of Chinese Nuclear Society (中國核學會核環保分會). Since October 2021, he has been the deputy chairman of Beijing CIAE-RIAR Radioisotope Technology Co., Ltd. Since December 2021, he has been the chairman of CNNC Qinshan Isotope Co., Ltd. (中核秦山同位素有限公司). Since August 2023, he has been the deputy chairman of Guangdong Xiai Pharmaceutical Co., Ltd.* (廣東希埃醫藥有限公司). Since May 2016, Mr. Fan has been the deputy general manager of the Company. Mr. Fan received a bachelor's degree in science (radiochemistry) from College of Chemistry of Sichuan University (formerly known as Sichuan United University) in July 1995. Mr. Fan is a senior engineer.

As at the date of this announcement, Mr. Fan did not hold any other positions with the Company or other members of the Group, nor did he hold any other directorships in the last three years in public companies, the securities of which are listed on any securities markets in Hong Kong or overseas.

As at the date of this announcement, Mr. Fan did not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company, nor did he have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571).

Mr. Fan will enter into a service contract with the Company for a term of three years, which is the same as the term of office of the fourth session of the board of directors of the Company, and he shall be eligible for re-election and re-appointment upon the expiry of his term of office. Mr. Fan will not receive any remuneration in respect of his appointment as an employee representative director of the Company.

Save as disclosed herein, there are no other matters relating to the appointment of Mr. Fan that need to be brought to the attention of the shareholders of the Company, nor is there any information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 10 November 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.